Devices Are Not Enough: Revitalizing Development of New Drugs for Cardiogenic Shock

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Roche Diagnostics; Abbott; 4Teen4; Windtree Therapeutics</li><li>Consultant Fee/Honoraria/Speaker’s Bureau - Roche Diagnostics; Bayer AG; MSD; Corteria; S-form Pharma; FIRE-1; Implicity; 4Teen4; Adrenomed</li></ul>